הכנסה תפעולית לפני ניכוי פחת: biomerica.com (BMRA)

Biomerica, Inc. (BMRA) is scaling its range of in vitro diagnostic systems to expand insurance coverage. EBITDA reflects current cash flow levels, where 0.00 serves as the current parameter value. Deliveries to clinics in Europe and the US provide geographical resilience, although the high density of players in the diagnostics sector creates risks of price dumping by industry behemoths.

This indicator reflects net cash flow from operating activities, allowing for a real-time assessment of the monetization efficiency of Biomerica, Inc. (BMRA) diagnostic solutions. By analyzing the distribution of EBITDA across periods, an investor can see how the implementation of InFoods tests into clinical practice converts into operating profit, which serves as the primary criterion for the business's fundamental stability and prevents the asset from being overvalued.